Anlotinib is another antiangiogenic drug, and in colorectal cancer, Anlotinib benefits the anti-PD-L1 immunotherapy by activating ROS/JNK/AP-1 pathway to upregulate PD-L1 expression (130). The gene discussed is CD274; the disease is colorectal cancer.